Khondrion: developing therapies for mitochondrial disease

Home

At Khondrion we want to make substantial contributions in developing a cure for patients like Mees and all others suffering from mitochondrial disease.

Patients with mitochondrial disease may present at any age, from birth to late adulthood. They generally suffer from progressive multi-system disorders for which no cure is available. A substantial part of mitochondrial patients die at an early age.

 Khondrion's portfolio includes long-lasting experience in mitochondrial medicine, unique quantitative life-cell technology, and  in-dept characterized human cell panels. Khondrion's pipeline includes new  and effective, lead compounds.  

Pipeline

Compound

Discovery

Preclinical

Phase I/II 

Phase III 

 

KH001 

 


 

 

 

 

KH002

 


 

 

 

 

KH003 

 


 

 

 

 

KH004 

 


 

 

 

Khondrion is supported by Energy4All  and partner organizations.